» Articles » PMID: 6234162

Immunologic Mechanisms of Parenchymal Lung Injury

Overview
Date 1984 Apr 1
PMID 6234162
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The lung, like most other organs, is susceptible to injury by circulating immune complexes, and also by humoral autoantibody and immune lymphocytes which specifically recognize selected lung antigens. In addition, by virtue of its direct communication with the external environment, the lung can also be injured by inhaled environmental agents which trigger inflammatory reactions mediated by immune effector systems. Although major emphasis to date has been placed on the ability of inhaled antigens to first sensitize, then provoke, immunologically specific reactions in the lung, there is increasing evidence to show that these same immune effector systems are also triggered in an immunologically nonspecific fashion by a certain environmental agents (termed "mitogens") which activate leukocytes in a polyclonal fashion. Such agents include certain viruses and other microorganisms, bacterial endotoxin, a wide variety of plant lectins, and certain chemicals, such as the phorbol esters. Although such agents act in an immunologically nonspecific fashion, they are nonetheless quite specific from a chemical viewpoint, and in many cases act by binding to specific receptors on the cell surface. By activating macrophages directly, and by activating much larger percentages of a given lymphocyte population than do specific antigens, they induce correspondingly amplified inflammatory reactions in vivo. Recent studies with animal models indicate that inhaled mitogens are strikingly effective in inducing pulmonary inflammation, whereas inhaled antigens (lacking mitogenic activity) produce little if any parenchymal injury in immunized recipients, unless administered in conjunction with a mitogen. Ongoing studies using such models promise to provide valuable new insight into the biologic properties which govern the pathogenicity of inhaled environmental agents, the mediators they release, and the biochemical basis for variations in individual susceptibility to injury by such agents.

Citing Articles

Safe use of PHI6 IN the experimental studies.

Sanmark E, Kuula J, Laitinen S, Oksanen L, Bamford D, Atanasova N Heliyon. 2023; 9(2):e13565.

PMID: 36879750 PMC: 9984441. DOI: 10.1016/j.heliyon.2023.e13565.


Polyclonal activators in pulmonary immune disease.

Willoughby W, Willoughby J, Gerberick G Clin Rev Allergy. 1985; 3(2):197-216.

PMID: 2985229 DOI: 10.1007/BF02992983.


Serum factor requirement for reactive oxygen intermediate release by rabbit alveolar macrophages.

Gerberick G, Willoughby J, Willoughby W J Exp Med. 1985; 161(2):392-408.

PMID: 2982990 PMC: 2187563. DOI: 10.1084/jem.161.2.392.

References
1.
Fearon D . Activation of the alternative complement pathway. CRC Crit Rev Immunol. 1979; 1(1):1-32. View

2.
Jennings L, Roholt O, Pressman D, Blau M, Andres G, Brentjens J . Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. I. The role of increased permeability of the alveolar capillary wall induced by oxygen. J Immunol. 1981; 127(1):129-34. View

3.
Pepys J . Immunopathology of allergic lung disease. Clin Allergy. 1973; 3(1):1-22. DOI: 10.1111/j.1365-2222.1973.tb01304.x. View

4.
Johnson K, Ward P . Acute immunologic pulmonary alveolitis. J Clin Invest. 1974; 54(2):349-57. PMC: 301562. DOI: 10.1172/JCI107770. View

5.
Rhodes R, Karnovsky M . Loss of macromolecular barrier function associated with surgical trauma to the intestine. Lab Invest. 1971; 25(3):220-9. View